title: No adverse impact on protection against pertussis from combined administration of Haemophilus influenza type b conjugate and diphtheria-tetanus toxoid-pertussis vaccines in the same syringe.
abstract: To assess whether combining a Haemophilus influenzae type b conjugate vaccine (PRP-T) and diphtheria-tetanus toxoid-pertussis (DTP) vaccine in a single syringe would impact adversely the antibody response and clinical protection conferred by pertussis vaccine, surveillance and a nested serosurvey were conducted among infants in a large-scale evaluation of PRP-T in Santiago. Infants received either combined PRP-T/DTP or DTP only at 2, 4, and 6 months of age. At 8 months, pertussis agglutinin, anti-pertussis toxin, and anti-filamentous hemagglutinin antibody levels in the PRP-T/DTP (137.7, 23.1, and 12.2, respectively) and DTP (142.9, 20.6, and 13.0, respectively) groups were comparable. The incidence of pertussis was similar among infants assigned to health centers administering combined PRP-T/DTP and those administering DTP alone (13.1 vs. 12.2 cases/10(5) child-years). Combined PRP-T/DTP vaccine did not diminish protection against pertussis.
authors.affiliation: Division of Geographic Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, USA.
authors.forename: O S
authors.initials: OS
authors.lastname: Levine
authors.forename: R
authors.initials: R
authors.lastname: Lagos
authors.forename: G A
authors.initials: GA
authors.lastname: Losonsky
authors.forename: O
authors.initials: O
authors.lastname: San Martin
authors.forename: P
authors.initials: P
authors.lastname: Abrego
authors.forename: C
authors.initials: C
authors.lastname: Bustamante
authors.forename: S S
authors.initials: SS
authors.lastname: Wasserman
authors.forename: M M
authors.initials: MM
authors.lastname: Levine
mesh_terms: D000372:Agglutination Tests; D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis; D000942:Antigens, Bacterial / Q000032:analysis; D001886:Bordetella pertussis / Q000276:immunology; D002677:Chile / Q000453:epidemiology; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007223:Infant; D016036:Seroepidemiologic Studies; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000009:adverse effects*; D014611:Vaccination / Q000009:adverse effects; D017778:Vaccines, Combined / Q000008:administration & dosage* / Q000009:adverse effects*; D014917:Whooping Cough / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D007074:Immunoglobulin G; D013745:Tetanus Toxoid; D017778:Vaccines, Combined